Biotie Therapies

biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. biotie's development has delivered selincro (nalmefene) for alcohol dependence, which received european marketing authorization in 2013 and is currently being rolled out across europe by partner h. lundbeck a/s. the current development products include tozadenant for parkinson's disease, which is in phase 3 development, and two additional compounds which are in phase 2 development for cognitive disorders including parkinson's disease dementia, and primary sclerosing cholangitis (psc), a rare fibrotic disease of the liver. biotie is a part of acorda therapeutics inc. group (”acorda”) and its shares, excluding of those owned by acorda, are currently subject to a redemption process in accordance with the finnish companies act.